The globalhospital acquired infections therapeutic marketsize is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research. The report“Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 – 2028”gives a detailed insight into current market dynamics and provides analysis on future market growth.
Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections. The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.
In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck’s Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older. This is expected to drive the market for hospital acquired infections therapeutic.
Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed. As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.
This has resulted in a rise in healthcare admissions and an increased possibility of getting an hospital acquired infection. Moreover, as per the data of the New York State Department of Health in November 2019, more than 40% of the adults in the state suffer from some form of chronic disorder, accounting for around 23% of all the hospitalizations.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below://m.jiayuancx.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request-for-sample
Asia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period. This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.
For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China. Thus, with increased hospital admissions, the market demand for hospital acquired infections therapeutics is bound to rise. Market participants such as Merck, Abbott Laboratories, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AbbVie Inc., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Limited and Allergan Plc.
betway苹果下载北极星市场研究分段医院acquired infections therapeutic market report on the basis of drug class, infection type, and region:
医院获得性感染的治疗,Drug Class Outlook (Revenue – USD Million, 2016 – 2028)
- Antibacterial Drugs
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- Others
- Antiviral Drugs
- Antifungal Drugs
医院获得性感染的治疗,Infection Type Outlook (Revenue – USD Million, 2016 – 2028)
- Urinary Tract Infections
- Ventilator-associated Pneumonia
- Surgical Site Infections
- Bloodstream Infections
- Other Hospital Infections
医院获得性感染的治疗,by Regional Outlook (Revenue – USD Million, 2016 – 2028)
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Netherlands
- Austria
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Central & South America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa